ES2116594T3 - Ansamicinas biciclicas y su uso como agentes antitumorales. - Google Patents

Ansamicinas biciclicas y su uso como agentes antitumorales.

Info

Publication number
ES2116594T3
ES2116594T3 ES94913896T ES94913896T ES2116594T3 ES 2116594 T3 ES2116594 T3 ES 2116594T3 ES 94913896 T ES94913896 T ES 94913896T ES 94913896 T ES94913896 T ES 94913896T ES 2116594 T3 ES2116594 T3 ES 2116594T3
Authority
ES
Spain
Prior art keywords
ansamicins
bicyclic
antitumoral agents
sup
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913896T
Other languages
English (en)
Inventor
Rodney C Schnur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2116594T3 publication Critical patent/ES2116594T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA (I) EN DONDE R{SUP, 1}, R{SUP, 2}, R{SUP, 3} Y X SON SEGUN SE DEFINE EN LA DESCRIPCION. TALES COMPUESTOS SON UTILES COMO INHIBIDORES DE LOS ONCOGENES Y COMO AGENTES ANTITUMORALES.
ES94913896T 1993-04-07 1994-03-14 Ansamicinas biciclicas y su uso como agentes antitumorales. Expired - Lifetime ES2116594T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/044,521 US5387584A (en) 1993-04-07 1993-04-07 Bicyclic ansamycins

Publications (1)

Publication Number Publication Date
ES2116594T3 true ES2116594T3 (es) 1998-07-16

Family

ID=21932854

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913896T Expired - Lifetime ES2116594T3 (es) 1993-04-07 1994-03-14 Ansamicinas biciclicas y su uso como agentes antitumorales.

Country Status (10)

Country Link
US (1) US5387584A (es)
EP (1) EP0693073B1 (es)
JP (1) JP2722280B2 (es)
AT (1) ATE166877T1 (es)
CA (1) CA2160137C (es)
DE (1) DE69410790T2 (es)
DK (1) DK0693073T3 (es)
ES (1) ES2116594T3 (es)
FI (1) FI106028B (es)
WO (1) WO1994022867A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
WO2000003737A2 (en) 1998-07-17 2000-01-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble drugs and methods for their production
US20020182268A1 (en) * 1998-12-07 2002-12-05 Bessette Steven M. Cancer treatment compositions and method using natural plant essential oils
ATE526019T1 (de) * 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
US7439359B2 (en) * 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
AU2002228772B2 (en) 2000-11-02 2005-12-08 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
CA2440809A1 (en) * 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
WO2002094196A2 (en) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
CA2460498A1 (en) * 2001-09-24 2003-04-03 Conforma Therapeutics Corporation Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
WO2003066005A2 (en) * 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
CA2481683A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US7241754B2 (en) * 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
CN100404029C (zh) * 2003-09-25 2008-07-23 中国医学科学院医药生物技术研究所 格尔德霉素（c-3559）在制备疱疹病毒生殖道感染药物中的应用
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6870049B1 (en) 2003-11-12 2005-03-22 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
AU2004309395C1 (en) * 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
AU2006230447A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
BRPI0608661A2 (pt) * 2005-04-07 2010-01-19 Conforma Therapeutics Corp formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica
MX2007013494A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag.
KR20080007642A (ko) * 2005-04-29 2008-01-22 코산 바이오사이언시즈, 인코포레이티드 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
US20100279994A1 (en) * 2005-06-21 2010-11-04 Inifinity Discovery, Inc. Ansamycin Formulations and Methods of Use Thereof
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
JP2009518302A (ja) * 2005-12-01 2009-05-07 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン含有組成物
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
WO2008128063A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
JP5454943B2 (ja) * 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
JP2011501731A (ja) * 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
EP2254586B1 (en) 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
JP2011514169A (ja) 2008-03-17 2011-05-06 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 幹細胞培養のためのマイクロキャリア
CN102014632B (zh) * 2008-04-29 2014-05-28 焦阳特制药股份有限公司 吲哚啉抗癌剂
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
KR20110090925A (ko) 2008-10-15 2011-08-10 인피니티 파마슈티컬스, 인코포레이티드 안사마이신 하이드로퀴논 조성물
WO2011040421A1 (ja) 2009-09-29 2011-04-07 武田薬品工業株式会社 スクリーニング方法
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
WO2011053257A2 (en) 2009-11-02 2011-05-05 Agency For Science, Technology And Research (A*Star) Methods of monitoring cellular states
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
CN103582645B (zh) 2011-04-22 2016-02-24 焦阳特制药股份有限公司 二氢氧茚吲哚类似物
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
US20190231694A1 (en) 2016-10-12 2019-08-01 Agency For Science, Technology And Research Method for lyophilising an exosome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug

Also Published As

Publication number Publication date
WO1994022867A1 (en) 1994-10-13
DE69410790D1 (de) 1998-07-09
CA2160137C (en) 1999-02-09
US5387584A (en) 1995-02-07
JPH08503960A (ja) 1996-04-30
EP0693073B1 (en) 1998-06-03
FI941580L (fi) 1994-10-08
DE69410790T2 (de) 1998-10-01
DK0693073T3 (da) 1998-10-12
ATE166877T1 (de) 1998-06-15
FI106028B (fi) 2000-11-15
CA2160137A1 (en) 1994-10-13
EP0693073A1 (en) 1996-01-24
FI941580A0 (fi) 1994-04-06
JP2722280B2 (ja) 1998-03-04

Similar Documents

Publication Publication Date Title
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
ES2161220T3 (es) 9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas como agentes antibioticos.
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
ES2119831T3 (es) 7-(sustituido)-9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
MX9700557A (es) Dihidrobenzofuranos.
ES2162617T3 (es) Nuevas 7-(sustituido)-8-(sustituido)-9-((glicilo sustituido)amido)-6-desmetil-6-desoxitetraciclinas.
FI950179L (fi) Kuplautuvia koostumuksia
MY111201A (en) New imidazopyridines
MX9205678A (es) Heteroarilaminas como nuevos inhibidores de la acetilcolinesterasa.
MX9302931A (es) Nuevas 4-aza-5&-colestan-onas 7b-substituidas como inhibidores de 5&-reductasa.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
BR9711586A (pt) Compostos e uso dos mesmo
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
ES2169150T3 (es) Compuestos a base de dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
MX9302116A (es) Compuestos azabiciclo.
JO1704B1 (en) New potent compounds
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693073

Country of ref document: ES